BioSpace News Archive

PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round

Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces that it has commenced an underwritten public offering of $175 million of shares of its common stock.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria (CIndU)

ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021 . Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer. HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) -- ImmunoGenesis, Inc., a clinical-stage biotechnology company developing therapeutics to catalyze effective immune respon

ADMA Biologics today announced an amendment to its existing senior secured term loan with Perceptive Advisors (“Perceptive”), which provides for an additional loan tranche of $15 million, increasing the total size of the credit facility to $100 million.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that it will be participating in the Targeted Radiopharmaceuticals Summit being held virtually December 8th – 10th.

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy results demonstrating that DNA medicine VGX-3100,

Incyte (Nasdaq:INCY) announced today that it will present at the 39 th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solut

SM-88 is an oral, investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different cancers New oral approach aimed at disrupting cancer metabolism in metastatic pancreatic cancer; ~ 58,000 cases annually in U.S. alone In clinical trials to date, SM-88 demonstrated a favorable safety profile

Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of industry veteran Brent Vaughan as Chief Executive Officer.